Geron stock leans on its myelofibrosis story
Geron's stock performance is closely linked to the commercial rollout of its lead product, Rytelo, for myelofibrosis. The biotechnology company, listed on Nasdaq, focuses on blood-cancer therapies, with execution in sales adoption and physician uptake being crucial for its market sentiment. Rytelo targets a specialized patient population, making clinical positioning and reimbursement key to revenue growth.
Form 4 Geron Corporation For: 1 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Geron Corporation on July 1st. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a class of the company's equity securities) whenever they trade shares in their own company. The article provides current market data for various indices, commodities, and stocks.
Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees
Geron Corp. (GERN) director Robert J. Spiegel received a grant of 6,103 shares of common stock on June 30, 2026, as compensation for his quarterly board retainer and committee fees. The shares were valued at $1.28 each, based on the closing price of the company's stock that day. Following this transaction, Spiegel directly holds 205,810 Geron common shares, a routine compensation award rather than an open-market purchase.
GERN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Geron Corporation (GERN) stock, indicating current stock performance, analyst opinions, and key financial metrics. It highlights GERN's present stock price, recent percentage changes, historical highs and lows, and upcoming earnings report date. The company's market capitalization, volatility, and employment figures are also discussed.
GERN Stock Steadies As Geron Builds Commercial Momentum
Geron Corporation (GERN) stock is experiencing a 7.14% increase due to positive sentiment surrounding its late-stage blood cancer therapy. The company has granted significant stock options to new employees, signaling aggressive talent acquisition, and is demonstrating commercial momentum with its approved RYTELO therapy and an ongoing Phase 3 trial. While revenue is rising, the company still faces negative profits and cash burn, positioning it as a catalyst-driven stock for traders.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced inducement grants of stock options to eight new employees, as specified under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments, with its drug RYTELO® approved for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced the grant of stock options to eight new employees as an inducement for their employment. These options, totaling 690,000 shares, have an exercise price of $1.23 per share and a ten-year term, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent to the biopharmaceutical company.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced it granted stock options to eight new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover an aggregate of 690,000 shares at an exercise price of $1.23 per share, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its telomerase inhibitor RYTELO® approved in the US and EU for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to eight new employees to purchase 690,000 shares of common stock. These inducement grants, effective June 17, 2026, were made under Nasdaq Listing Rule 5635(c)(4) with an exercise price of $1.23 per share. The options have a ten-year term and vest over four years, subject to continued employment.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to eight new employees to purchase 690,000 shares of common stock. These grants were made as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.23 per share, a ten-year term, and vest over four years, subject to continued employment.
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Geron Corp (GERN), listing major institutional shareholders like RA Capital Management and BlackRock. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent changes in shareholdings by key investors. The report also lists ETFs that hold GERN shares.
Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article "Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution" from TradingKey states that relevant revenue data by business segment and region has not been disclosed by the company yet. It provides current stock information for Geron Corp (GERN), including its share price, market cap, and links to other financial analysis tools, but no detailed revenue breakdown.
Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Geron Corp (GERN) stock, focusing on its historical dividends and stock splits. It indicates that Geron Corp has not distributed any dividends over the past five years and there is no data available for historical stock splits. The piece presents current stock performance data, including its price and market capitalization.
Geron (GERN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary
This article summarizes Geron's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, highlighting the company's transition to a commercial stage with its drug RYTELO. RYTELO, approved for lower-risk MDS, is seeing increasing uptake and is positioned as a preferred second-line agent, with Geron focusing on commercialization, education, and financial discipline for long-term growth. The company is actively targeting high-volume community physicians and reinforcing clinical outcomes with real-world data.
GERN Stock Builds Momentum On Strong RYTELO Data
Geron Corporation (GERN) stock is gaining momentum, trading up 10.36% due to positive real-world data for its drug RYTELO in lower-risk myelodysplastic syndromes (MDS). The data shows a 37.5% red blood cell transfusion independence rate, consistent with Phase 3 trials and suggesting better outcomes with earlier treatment. The company plans multiple presentations at EHA and ASCO, indicating a robust pipeline beyond MDS and a strategy to build a telomerase inhibitor franchise across various blood cancers.
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch
Geron Corp has transitioned into a commercial-stage biotech after receiving FDA approval for its blood cancer drug imetelstat to treat lower-risk myelodysplastic syndromes (MDS) following positive Phase 3 data. The company's focus is now on the commercial launch, including pricing, reimbursement, and market access in the US, while also continuing to invest in clinical development to expand imetelstat into additional indications like myelofibrosis. Investors are closely watching initial sales metrics and future clinical and regulatory milestones.
Why Did GERN Stock Tumble 10% Pre-Market Today?
Geron's stock (GERN) tumbled over 10% pre-market after its fourth-quarter and full-year 2025 results showed total revenue and loss per share falling below analysts' estimates. Despite this, net product sales for its blood cancer therapy RYTELO reached $48 million in Q4, with sales and demand climbing, and the company projects RYTELO revenue between $220 million and $240 million for 2026. Retail sentiment on Stocktwits remained bullish even as the stock declined.
Geron Corp stock (US3741631036): Focus on valuation as short interest eases
Geron Corp shares are trading around the USD 1 mark on Nasdaq, with investors weighing recent pullbacks, short interest data, and valuation metrics. As of mid-May 2026, short interest saw a 7.3% decline, indicating a slight easing of bearish sentiment. Given Geron is a development-stage biotech, its valuation is driven by expectations of future clinical and regulatory milestones rather than traditional earnings multiples.
GERN - Geron Corp Stock Price and Quote
This article provides comprehensive stock information for Geron Corp (GERN), including its latest stock price, financial overview, key statistics, and a history of analyst ratings. It also lists recent news and press releases related to the company's financial results, corporate appointments, and product development, specifically surrounding its telomerase inhibitor, Imetelstat.
GERN SEC Filings - Geron Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Geron Corp (GERN) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-generated summaries and sentiment analysis. Key filings include the appointment of Harout Semerjian as the new CEO with details on his compensation and equity inducement, as well as various quarterly earnings and material event reports. The platform tracks 45 SEC filings for GERN, offering tools and insights for investors and traders.
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Geron Corporation announced that its management team will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, to participate in a fireside chat. The biopharmaceutical company focuses on changing the course of blood cancer with its approved telomerase inhibitor RYTELO® (imetelstat) and is conducting further trials for other hematologic malignancies. A live webcast of the fireside chat will be available on Geron's website.
Geron plans Goldman Sachs healthcare fireside chat, webcast June 8
Geron (Nasdaq: GERN) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, where company management will host a fireside chat on Monday, June 8, 2026, at 8:40 a.m. ET in Miami, Florida. A live and archived audio webcast of the event will be available on Geron's website. The announcement highlights Geron's continuous engagement with investors, following recent updates on RYTELO® commercialization and Q1 2026 results.
GERN - Aging Population Trends Will Expand Hematology Market Opportunity
Analysts have slightly revised down Geron's price target due to more conservative assumptions regarding revenue growth, profit margins, and future P/E, though the intrinsic fair value estimate remains unchanged. Bullish analysts see this as a fine-tuning, while bearish analysts view it as a recognition that prior expectations might have been overly optimistic. Key drivers for Geron include an expanding patient pool due to an aging population, strong adoption of RYTELO, and potential pipeline expansion, though risks include reliance on a single drug and execution challenges in new launches.
Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan
Geron Corporation's stockholders approved an amendment to its 2018 Equity Incentive Plan, increasing the number of common shares issuable under the plan by 4,500,000. This approval, alongside the election of directors and other proposals, occurred at the virtual 2026 Annual Meeting held on May 20, 2026. The amendment impacts future equity-based compensation awards, and details are available in the company's SEC filings.
Geron (GERN) awards director Susan Molineaux 220,000 stock options
Geron Corp director Susan Molineaux was granted stock options for 220,000 shares of common stock at an exercise price of $1.26 per share. This equity award vests fully on the earlier of the next annual stockholder meeting or the first anniversary of the grant date, contingent on her continuous service. The options will expire on May 19, 2036, if not exercised.
Geron (GERN) director Dawn Carter Bir awarded 220,000 stock options
Geron Corp director Dawn Carter Bir was granted options to acquire 220,000 shares of Geron common stock at an exercise price of $1.26 per share on May 20, 2026. The options, which expire on May 19, 2036, will vest and become exercisable on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date, contingent on her continuous service. This transaction is categorized as a compensation award rather than an open-market purchase.
Geron (NASDAQ: GERN) director awarded 220,000 options at $1.26 strike
Geron Corp director Robert J. Spiegel was granted 220,000 stock options with an exercise price of $1.26 per share, expiring on May 19, 2036. The options will vest 100% on the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date, provided Spiegel remains in continuous service. This transaction is classified as a compensation award, not an open-market purchase or sale.
Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26
Geron (NASDAQ: GERN) director Elizabeth G. O'Farrell was granted stock options for 220,000 shares of common stock with an exercise price of $1.26 per share. These options, which vest upon the earlier of the next annual stockholder meeting or the first anniversary of the grant date, expire on May 19, 2036. This transaction is classified as a grant or award of derivative securities, not a purchase or sale of shares.
Geron (GERN) Q1 2026 Earnings Call Transcript
Geron Corporation held its Q1 2026 earnings call, reporting RYTELO net revenue of $51.8 million, a 31% year-over-year increase, and reiterated its full-year revenue guidance of $220 million to $240 million. The company emphasized strong commercial execution, effective cost control, and progress in its European commercial strategy, with updates expected before year-end. Geron also highlighted the inclusion of imetelstat (RYTELO) in NCCN guidelines as a preferred second-line option for lower-risk MDS and anticipates the IMpactMF trial's interim analysis in the second half of 2026.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to five newly hired employees as an inducement to their employment, a move compliant with Nasdaq Listing Rule 5635(c)(4). These options cover an aggregate of 333,750 shares with an exercise price of $1.29 per share, matching the closing price on the grant date. The options have a ten-year term and a four-year vesting schedule, reinforcing Geron's commitment to attracting and retaining talent.
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus
Geron Corp has awarded new stock options to five recent hires under Nasdaq's inducement rules, signaling continued team expansion as the company advances its commercial-stage blood cancer franchise. These grants are designed to attract talent in critical functions without requiring shareholder approval, reflecting a common biotechnology practice to align new employees with long-term value creation. The move underscores Geron's growth following regulatory progress with its lead asset, imetelstat, a telomerase inhibitor for hematologic malignancies.
Five new Geron hires receive options for 333,750 shares
Geron (Nasdaq: GERN) granted stock options for an aggregate 333,750 shares to five new employees on May 15, 2026. These inducement awards, with an exercise price of $1.29 per share, have a ten-year term and a four-year vesting schedule, aligning with Nasdaq Listing Rule 5635(c)(4). The grants are part of Geron's ongoing efforts as a commercial-stage biopharmaceutical company focusing on blood cancer treatments.
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Geron Corp (GERN), detailing its revenue breakdown, profitability margins, and a comparison with competitors. GERN boasts a high gross margin of 96.74% but shows negative operating and net margins, as well as a negative Return on Equity. The article also benchmarks GERN against industry leaders SEPN and MRVI, highlighting its market capitalization and gross margin performance relative to them.
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026)
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, disclosing beneficial ownership of 31,720,278 shares of Geron Corp. (GERN) common stock, representing 4.95% of the class. The filing indicates shared voting and dispositive power over these shares, calculated against 640,544,661 outstanding shares as of February 20, 2026. This passive investment report indicates the stake is below 5%, with future disclosures only required for changes in ownership or classification.
RYTELO study: 37.5% of transfusion-dependent went 8 weeks transfusion-free
Geron (Nasdaq: GERN) announced that the first real-world evidence study of its drug RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) will be presented at EHA 2026. The study, conducted at Moffitt Cancer Center, involved 40 heavily pretreated, transfusion-dependent LR-MDS patients and showed that 37.5% achieved red blood cell transfusion independence for at least eight weeks, with a safety profile consistent with previous data. Geron will also present updated myelofibrosis overall survival data and early-phase acute myeloid leukemia and myelofibrosis combination trial data at EHA 2026 and ASCO 2026.
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?
Geron Corporation (NASDAQ: GERN) is highlighted as one of the best US stocks under $5, with Wedbush reiterating an Outperform rating and a $5 price target. The company reported strong Q1 2026 net product revenue of $51.8 million from RYTELO, an 8% increase from Q4 2025, and maintains its 2026 revenue guidance between $220 million and $240 million. Geron is also advancing investigator-sponsored trials for RYTELO and strengthening its supply chain.
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts
Geron Corporation (NASDAQ:GERN) has received an average "Hold" rating from six analysts, with two recommending "sell," two "hold," and two "buy." The consensus 12-month price target for the stock is $2.50, significantly higher than its current trading price of $1.39. Despite the mixed analyst sentiment, Geron recently surpassed earnings and revenue expectations in its latest quarterly report, driven by progress with its lead drug candidate, imetelstat.
1GERN.MI Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (BIT:1GERN)
This article provides a technical analysis of GERON CORP (BIT:1GERN), noting its poor technical rating of 3 out of 10 and underperformance in the biotechnology industry. While both short-term and long-term trends are positive, the short-term picture is negative, and the stock is trading within a tight range. The analysis includes a breakdown of various technical indicators like RSI and MACD, support/resistance levels, and common chart patterns.
Geron Corporation (NASDAQ:GERN): Is Breakeven Near?
This article analyzes Geron Corporation's financial performance and future profitability outlook, assessing if and when the company might reach breakeven. It will likely delve into recent earnings, expenses, and revenue projections to determine the path to financial sustainability for the pharmaceutical company.
Can Geron’s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?
Geron Corporation reported improved first-quarter 2026 results with revenue rising to US$51.84 million and net loss narrowing significantly to US$3.64 million due to its commercial ramp. This improvement supports the short-term earnings narrative but the company still faces risks such as single-drug dependence and capital needs for its expanding pipeline. Upcoming investor conferences are expected to provide more details on how these results align with future revenue guidance and diversification plans for its blood cancer programs.
GERN Stock Slips As Traders Weigh Biotech Cash Burn
Geron Corporation (GERN) stock has slipped by 6.96% as traders evaluate its financial profile, characterized by significant cash reserves but ongoing losses typical of a development-stage biotech. The company holds strong liquidity with $312.4M in cash against $73.6M in current liabilities, providing a substantial runway for R&D despite quarterly operating cash outflows of $62.9M. Technical analysis indicates a short-term downtrend with resistance forming, prompting traders to seek quick scalps rather than long-term positions until clearer catalysts or trend changes emerge.
Geron (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) reported strong Q1 2026 financial results with RYTELO net revenue up 31% year-over-year to $51.8 million, placing the company on track for its $220-$240 million annual guidance. The earnings call highlighted strategic priorities including continued U.S. commercial execution for RYTELO, advancement of European commercial and pricing strategies, and maintaining financial discipline with reduced operating expenses. Management also expects interim analysis results from the IMpactMF trial in relapsed/refractory myelofibrosis in H2 2026, which could further support the disease-modifying potential of imetelstat.
Geron Corp reports results for the quarter ended March 31 - Earnings Summary
Geron Corp has released its earnings summary for the quarter ended March 31. The report, provided by Refinitiv, gives an overview of the company's financial performance. This information is critical for investors and analysts following GERN.
Geron 1Q Loss/Shr 1c >GERN
Geron reported a first-quarter loss per share of 1 cent. The company's stock symbol is GERN.
[10-Q] GERON CORP Quarterly Earnings Report
Geron Corporation has released its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The report details the company's financial performance, including a net loss of $3.6 million, an increase in product revenue from RYTELO, and significant research and development expenses. It also discusses ongoing legal proceedings, risk factors related to RYTELO's commercialization, regulatory approvals, intellectual property, and financial stability, emphasizing the company's dependence on RYTELO's success and its need for careful capital management.
Geron: Q1 Earnings Snapshot
Geron Corp. (GERN) reported a first-quarter loss of $3.6 million, or 1 cent per share, which exceeded Wall Street expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 3 cents per share. The drugmaker also announced revenue of $51.8 million for the period.
Geron Corporation Reports $290.6 Million in Cash Reserves for First Quarter 2026
Geron Corporation announced its financial results for the first quarter of 2026, reporting $290.6 million in cash and marketable securities as of March 31, 2026. The company also detailed research and development expenses of $29.4 million and general and administrative costs of $11.3 million for the quarter. Geron continues to advance its clinical development programs and prepare for potential regulatory submissions.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation announced its first-quarter 2026 financial results, reporting RYTELO net product revenue of $51.8 million, an 8% increase from Q4 2025. The company reiterated its full-year 2026 guidance for RYTELO net product revenue ($220M-$240M) and total operating expenses ($230M-$240M) and highlighted progress in commercial strategy and leadership appointments. Geron ended Q1 2026 with $341 million in cash, cash equivalents, restricted cash, and marketable securities, with a net loss of $3.6 million.
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron (GERN) reported a Q1 loss of $0.01 per share, beating the Zacks Consensus Estimate of a $0.03 loss, and posted revenues of $51.84 million, surpassing estimates by 2.94%. The company has outperformed the S&P 500 this year, with shares adding about 25%, and currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance. The medical-biomedical and genetics industry, however, is in the bottom 40% of Zacks-ranked industries.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation announced strong first-quarter 2026 financial results, achieving $51.8 million in RYTELO net product revenue, an 8% increase from the previous quarter. The company reiterated its 2026 revenue guidance of $220 million to $240 million and detailed strategic initiatives including European commercial strategy development, advancement of its Phase 3 IMpactMF trial, and overall financial discipline. Geron also reported a significant decrease in net loss compared to Q1 2025, largely due to increased RYTELO revenue and reduced operating expenses.
